Alejandrina Rodríguez-Hernández

Dr. Alejandrina Rodríguez-Hernández


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 October 2020 in Nanomaterials
Verified
Journal Article
Open access
PDF file
Adolfo Virgen-OrtizAdolfo Virgen-Ortiz
Adolfo Virgen-Ortiz
AAAlejandro Apolinar-Iribe
Alejandro Apolinar-Iribe
IDIrene Díaz-Reval
Irene Díaz-Reval
HPHortensia Parra-Delgado
Hortensia Parra-Delgado
SLSarai Limon-Miranda
Sarai Limon-Miranda
ARAlejandrina Rodríguez-Hernández
Alejandrina Rodríguez-Hernández
Different studies in experimental diabetes models suggest that zinc oxide nanoparticles (ZnONPs) are useful as antidiabetic agents. However, this evidence was performed and measured in long-term treatments and with repeated doses of ZnONPs. This work aimed to evaluate the ZnONPs acute effects on glycemia during the next six h after an oral or intraperitoneal administration of the treatment in healthy and diabetic rats. In this study, the streptozotocin-nicotinamide intraperitoneal administration in male Wistar rats were used as a diabetes model. 10 mg/kg ZnONPs did not modify the baseline glucose in any group. Nevertheless, the ZnONPs short-term administration (100 mg/kg) induced a hyperglycemic response in a dose and route-dependent administration in healthy (130 ± 2 and 165 ± 10 mg/dL with oral and intraperitoneal, respectively) and diabetic rats (155 ± 2 and 240 ± 20 mg/dL with oral, and intraperitoneal, respectively). The diabetic rats were 1.5 fold more sensitive to ZnONPs effect by the intraperitoneal route. In conclusion, this study provides new information about the acute response of ZnONPs on fasting glycemia in diabetic and healthy rat models; these data are essential for possible future clinical approaches.

30 August 2020 in Molecules
Verified
Journal Article
Open access
PDF file
FAFelipa Andrade
Felipa Andrade
CRCinthia Rangel
Cinthia Rangel
ARAlejandrina Rodríguez-Hernández
Alejandrina Rodríguez-Hernández
ELEvelyn López-Dyck
Evelyn López-Dyck
AEAlejandro Elizalde
Alejandro Elizalde
ESEnrique Sanchez-Pastor
Enrique Sanchez-Pastor
The aim of this work was to determine whether Capsaicin may exert a vascular regulation through the activation of CB1 and/or CB2 receptors causing vasorelaxation in the rat aorta. Our results show the location of TRPV1 mainly in the endothelial and smooth muscle cells membrane. Nevertheless, Capsaicin caused vasorelaxation of this artery through a mechanism independent of TRPV1, since the specific antagonists Capsazepine and SB-366791 did not block the effect of Capsaicin. Because the significant expression of CB1 and CB2 receptors has been previously reported in the rat aorta, we used antagonists for these two receptors prior to the addition of Capsaicin. In these experiments, we found that the inhibition of CB1 using AM281, decreases the vasorelaxant effect caused by Capsaicin. On the other hand, the vasorelaxant effect is not altered in the presence of the CB2 receptor antagonist AM630. Furthermore, a partial decrease of the effect of Capsaicin was also seen when L-type calcium channels are blocked. A complete block of Capsaicin-induced vasorelaxation was achieved using a combination of Verapamil and AM281. In accordance to our results, Capsaicin-induced vasorelaxation of the rat aorta is neither dependent of TRPV1 or CB2 receptors, but rather it is strongly suggested that a tandem mechanism between inactivation of L-type calcium channels and the direct activation of CB1 receptors is involved. These findings are supported by CB1 docking simulation which predicted a binding site on CB1 receptors for Capsaicin.

12 February 2024 in Journal of Nutrition and Metabolism
Verified
Journal Article
Open access
PDF file
SCSalma I. Cortes-Alvarez
Salma I. Cortes-Alvarez
Ivan Delgado-EncisoIvan Delgado-Enciso
Ivan Delgado-Enciso
ARAlejandrina Rodríguez-Hernández
Alejandrina Rodríguez-Hernández
Gustavo A. Hernandez-FuentesGustavo A. Hernandez-Fuentes
Gustavo A. Hernandez-Fuentes
NANomely S. Aurelien-Cabezas
Nomely S. Aurelien-Cabezas
CSCarmen A. Sánchez-Ramirez
Carmen A. Sánchez-Ramirez
Moringa oleifera (MO) is a native tree of Asia and is cultivated in some areas of Mexico as part of traditional horticulture. The aim of the present study was to compare the efficacy of MO infusion vs. MO ethanolic extract for the simultaneous treatment of nonalcoholic fatty liver (NAFLD), hyperlipidemia, and hyperglycemia in a murine model fed with a high-fat diet (HFD). BALB/c mice were fed a balanced diet (healthy control) or an HFD for 6months. With this, the NAFLD model was established before starting a therapeutic intervention with MO for two months. The phytochemical analysis by nuclear magnetic resonance in 1H and 13C experiments showed signals for pyrrole alkaloids and triterpenes as the main constituents of the extract and infusion preparation. A significant reduction of SGPT, SGOT, lipids, urea, and glucose in blood among NAFLD groups treated with MO (infusion or extract) was found, when compared to the NAFLD-placebo group. Steatosis and liver inflammation were found to be decreased in the MO groups, as infusion or ethanolic extract. Infusion produced a better therapeutic effect than the extract in all parameters, except glycemic control, where the extract was better. As an additional finding, it is noteworthy that treatment with MO, particularly through infusion, resulted in improved motor activity. Moreover, a reduction in anxiety-like behavior was observed exclusively with the administration of infusion. These observations provide valuable insights into the potential broader effects of Moringa oleifera beyond the primary aim of the study.

7 September 2021 in Nanomaterials
Verified
Journal Article
Open access
PDF file
Adriana Ceballos-GutiérrezAdriana Ceballos-Gutiérrez
Adriana Ceballos-Gutiérrez
ARAlejandrina Rodríguez-Hernández
Alejandrina Rodríguez-Hernández
MÁMaría del Rosario Álvarez-Valadez
María del Rosario Álvarez-Valadez
SLSarai Limon-Miranda
Sarai Limon-Miranda
FAFelipa Andrade
Felipa Andrade
Adolfo Virgen-OrtizAdolfo Virgen-Ortiz
Adolfo Virgen-Ortiz
ZnO nanoparticles (ZnONPs) have been shown to have therapeutic potential in some diseases such as diabetes and cancer. However, concentration-dependent adverse effects have also been reported. Studies which evaluate the effects of ZnONPs on the cardiovascular system are scarce. This study aimed to evaluate the cardiovascular effects of a low dose of ZnONPs administered chronically in healthy rats. Changes in dyslipidemia biomarkers, blood pressure, aortic wall structure, vascular contractility, and expression of cannabinoid receptors in the aorta wall were evaluated. Healthy rats were divided into two groups: control or treated (one, two, and three months). The treated rats received an oral dose of 10 mg/kg/day. The results showed that treatment with ZnONPs induced dyslipidemia from the first month, increasing atherosclerosis risk, which was confirmed by presence of atherosclerotic alterations revealed by aorta histological analysis. In in vitro assays, ZnONPs modified the aorta contractile activity in response to the activation of cannabinoid receptors (CB1 and CB2). The expression of CB1 and CB2 was modified as well. Moreover, ZnONPs elicited an increase in blood pressure. In conclusion, long-time oral administration of ZnONPs induce dyslipidemia and atherosclerosis eliciting alterations in aorta contractility, CB1 and CB2 receptors expression, and an increase in blood pressure in healthy rats.

11 November 2022 in Molecules
Verified
Journal Article
Open access
PDF file
MLMarisa López
Marisa López
LQLAURA OLIVIA QUINTERO
LAURA OLIVIA QUINTERO
MHMiguel Huerta
Miguel Huerta
ARAlejandrina Rodríguez-Hernández
Alejandrina Rodríguez-Hernández
VMValery Melnikov
Valery Melnikov
MRMonica Rios-Silva
Monica Rios-Silva
Iron overload (IOL) increases the risk of diabetes mellitus (DM). Capsaicin (CAP), an agonist of transient receptor potential vanilloid-1 (TRPV1), reduces the effects of IOL. We evaluated the effects of chronic CAP administration on hepcidin expression, kidney iron deposits, and urinary biomarkers in a male Wistar rat model with IOL and DM (DM-IOL). IOL was induced with oral administration of iron for 12 weeks and DM was induced with streptozotocin. Four groups were studied: Healthy, DM, DM-IOL, and DM-IOL + CAP (1 mg·kg−1·day−1 for 12 weeks). Iron deposits were visualized with Perls tissue staining and a colorimetric assay. Serum hepcidin levels were measured with an enzyme-linked immunosorbent assay. Kidney biomarkers were assayed in 24 h urine samples. In the DM-IOL + CAP group, the total area of iron deposits and the total iron content in kidneys were smaller than those observed in both untreated DM groups. CAP administration significantly increased hepcidin levels in the DM-IOL group. Urinary levels of albumin, cystatin C, and beta-2-microglobulin were similar in all three experimental groups. In conclusion, we showed that in a DM-IOL animal model, CAP reduced renal iron deposits and increased the level of circulating hepcidin.

2 June 2022 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
SZSergio A Zaizar-Fregoso
Sergio A Zaizar-Fregoso
BPBrenda Astrid Paz-Michel
Brenda Astrid Paz-Michel
ARAlejandrina Rodríguez-Hernández
Alejandrina Rodríguez-Hernández
JPJuan Paz-García
Juan Paz-García
NANomely S. Aurelien-Cabezas
Nomely S. Aurelien-Cabezas
Ivan Delgado-EncisoIvan Delgado-Enciso
Ivan Delgado-Enciso
Rheumatoid arthritis is globally present in about 1% of the population. This autoinflammatory disease modifies the connective tissue, causing pain and inflammation of the joints. Over time, it causes the loss of joint cartilage and bone mass, decreasing the patient's quality of life. Treatment options now available either give symptomatic alleviation or alter the disease process. Nonetheless, adherence to chronic treatment is typically limited due to adverse effects. As a result, new therapy approaches, such as systemic administration of neutral electrolyzed saline to improve patients’ quality of life, are being investigated. The study is a randomized prospective preclinical trial with a single-blind and a 4-arm parallel group using a collagen-induced mice model to generate rheumatoid arthritis. It was carried out on 36 male BALB/c mice, with the primary outcome measure being a scoring system for histopathologic assessment. When all groups are compared, there are significant differences. In addition, the animal model was validated by the healthy group. The animals treated with neutral electrolyzed saline had much less cartilage degradation, bone erosion, pannus development, and inflammation than the placebo-treated mice. Serum IL-6 levels were evaluated in parallel with disease severity expressed as synovitis grading of the affected joints. Spearman’s rank correlation coefficient (Rs) = 0.399 ( ) between serum IL-6 levels and the synovitis grading suggests a direct correlation between IL-6 production and disease severity. An additional trial of 20 male BALB/c mice (10 treated with placebo and 10 with neutral electrolyzed saline for 30 days) showed no clinical nor histopathological evidence of adverse effects. According to histopathological and blood test results, we conclude that neutral electrolyzed saline minimizes mechanical and inflammatory damage to the joint and may be helpful as an alternative to rheumatoid arthritis therapy.